Gastroenterology News

A novel duodenal mucosal renewal procedure followed by once-weekly semaglutide could allow adults with type 2 diabetes to maintain glycemic control without insulin therapy, according to a speaker.

Disease-free survival at 3 years was significantly higher among patients with screen-detected colorectal cancer vs. those with clinically detected CRC, according to a study conducted in the Netherlands.

In this Healio video, Edward V. Loftus Jr., MD, previews this month’s Healio Exclusive, in which experts tout the positive attributes of Janus kinase inhibitors for inflammatory bowel disease and discuss their role in the treatment landscape.

The human leukocyte antigen DRB1*01:03 allele was associated with severe ulcerative colitis, along with greater odds for major operation, hospitalization and corticosteroid use, according to results of a Danish study.

The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.

This month’s Healio Exclusive highlights the efficacy of Janus kinase inhibitors in the management of ulcerative colitis and Crohn’s disease.

Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.

Over three decades, changes to organ allocation policies were associated with reduced waitlist mortality and increased rates of liver transplant among children with pediatric acute liver failure, according to research in JAMA Surgery.

Zyno Medical is recalling select Z800 infusion pumps due to a defect in the air-in-line software algorithm that may allow a 1 mL air bubble to be passed on to a patient, according to the FDA.

When investing, time in the market is arguably as important as well-publicized factors, such as rate of return, initial amount of investment (principal) and costs of investing.